Loading...
Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
An article in a recent edition of Current Oncology explored the validation of progression-free survival (pfs) as an endpoint in clinical trials of antineoplastic agents for metastatic colorectal cancer, metastatic renal cell carcinoma, and ovarian cancer. The support for pfs as a surrogate endpoint...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Multimed Inc.
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3615866/ https://ncbi.nlm.nih.gov/pubmed/23559882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1226 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|